Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Rifkin

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Psychiatric Research|November 13, 2020
Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sitesYiftach Roth, Aron Tendler, Mehmet Kemal Arikan, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVania Hungria, Pawel Robak, Marek Hus, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Psychiatric Research|November 13, 2020
Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sitesYiftach Roth, Aron Tendler, Mehmet Kemal Arikan, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVania Hungria, Pawel Robak, Marek Hus, et al.
Pageof 3